| General information about company | | | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|--|--|--|--|--|--|
| Name of The Company | CAPLIN POINT LABORATORIES LIMITED | | | | | | |
| BSE Scrip Code | 524742 | | | | | | |
| NSE Symbol | CAPLIPOINT | | | | | | |
| MSE Symbol | NOTLISTED | | | | | | |
| Date of Start of Financial Year | 01-04-2021 | | | | | | |
| Date of End of Financial Year | 31-3-2022 | | | | | | |
| Reporting Period | Second half yearly | | | | | | |
| Date of Start of Reporting Period | 01-10-2021 | | | | | | |
| Date of End of Reporting Period | 31-03-2022 | | | | | | |
| Level of rounding to be used in disclosing related party transactions | Crores | | | | | | |
| Whether the company has any related party? | Yes | | | | | | |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes | | | | | | |

| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the ter applicable/offered to all shareholders/public | erms uniformly | NA |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|----|
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 0 allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the set rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Cl & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | chedule of interest | NA |
| (III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)? | : | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting R the day of results publication? | RPT disclosures on | |
| (b) If answer to above question is No, please explain the reason for not complying. | | |

| | | | | | | | | R | elated pa | rty transa | ctions | | | | | | | | | | | |
|--------|-----------------------------------------|----------------------------------------------------|------------------------------------|-------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------|--------------------|------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------|----------------|---------|------------------------------------------------------------------------|-------------------------------------|---------|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------|----------------------------|
| | | | | | | | | | | | | | loans, into | r-corporate de | eposits | , advan | insactions - app ces or investme | nts mad | e or given by | the listed e | ntity/subsidia | ry. These |
| | entity /subsi | ne party (listed diary) entering transaction | Detail | s of the counterp | arty | | Value of the related | | | reporting | In case monies are due to either party as a result of the transaction | | | | | ace, during the reporting period when such | | | | | | |
| Sr No. | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Type of related party transaction transaction | party transaction as approved by the audit committee | Remarks on approval by audit committee | Opening balance | | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | Notes | |
| 1 | Caplin Point Laboratories Limited | | Drogueria Saimed De Honduras | | Wholly owned step down Subsidiary | Sale of goods or services | | 30 | NA | 27.8 | 10.14 | -1.48 | | | | | | | | | | Textual Information(1) |
| 2 | Caplin Point Laboratories Limited | | Nuevos Eticos Neoethicals | | Step Down Subsidiary | Sale of goods or services | | 150 | NA | 58.86 | 3.72 | 10.85 | | | | | | | | | | Textual Information(2) |
| 3 | Caplin Point Laboratories Limited | | Neo Ethicals CIA | | Wholly owned step down Subsidiary | Sale of goods or services | | 30 | NA | 13.91 | -3 | 0.3 | | | | | | | | | | Textual Information(3) |
| 4 | Caplin Point Laboratories Limited | | Neo Ethicals SA | | Wholly owned step down Subsidiary | Sale of goods or services | | 30 | NA | 13.36 | 9.17 | -14.84 | | | | | | | | | | Textual Information(4) |
| 5 | Caplin Point Laboratories Limited | | Ashvich Infotek Private Limited | | Promoter Group | Any other transaction | Rent & Consultancy | 0.75 | NA | 0.56 | 0.0659097 | 0.0413221 | | | | | | | | | | Textual Information(5) |
| 6 | Caplin Point Laboratories Limited | | Caplin Steriles Limited | | Subsidiary | Purchase of goods or services | | 2.6 | NA | 0.94 | 0 | 0 | | | | | | | | | | Textual Information(6) |
| 7 | Caplin Point Laboratories Limited | | Caplin Steriles Limited | | Subsidiary | Purchase of fixed assets | | 2.6 | NA | 0.11 | 0 | 0 | | | | | | | | | | Textual Information(7) |
| 8 | Caplin Point Laboratories Limited | | Caplin Steriles Limited | | Subsidiary | Sale of goods or services | | 2.6 | NA | 0.02 | 0 | 0 | | | | | | | | | | Textual Information(8) |
| 9 | Caplin Point Laboratories Limited | | Caplin Steriles Limited | | Subsidiary | Sale of fixed assets | | 2.6 | NA | 1.06 | 0 | 0 | | | | | | | | | | Textual Information(9) |
| 10 | Caplin Point Laboratories Limited | | Caplin Steriles Limited | | Subsidiary | Any other transaction | Reimbursement of expenses | 2.6 | NA | 0.39 | 0 | 0 | | | | | | | | | | Textual Information(10) |
| 11 | Caplin Point Laboratories Limited | | Caplin Steriles Limited | | Subsidiary | Loan | | 140 | NA | 22.15 | 17.6 | 39.75 | | | | | Loan | 0.09 | 7 years (2yrs moratorium + 5 years repayment) | Unsecured | For Capex Project | Textual Information(11) |
| 12 | Caplin Point Laboratories Limited | | Dr. Sridhar Ganesan | | Key Management Personnel | Remuneration | | | NA | 0.29 | 0 | 0 | | | | | | | | | | Textual Information(12) |
| 13 | Caplin Point Laboratories Limited | | Mr. Muralidharan D | | Key Management Personnel | Remuneration | | | NA | 0.25 | 0 | 0 | | | | | | | | | | Textual Information(13) |
| 14 | Caplin Point Laboratories Limited | | Mr. Muralidharan D | | Key Management Personnel | Any other transaction | Equity Shares Pursuant to employees stock option scheme | | NA | 0.39 | 0 | 0 | | | | | | | | | | Textual Information(14) |
| 15 | Caplin Point Laboratories Limited | | Mr. Partheeban Vivek Siddarth | | Chief Operating Officer | Remuneration | | | NA | 0.1 | 0 | 0 | | | | | | | | | | Textual Information(15) |
| 16 | Caplin Point Laboratories Limited | | Mr. Dinesh R G | | Key Management Personnel | Remuneration | | | NA | 0.05 | 0 | 0 | | | | | | | | | | Textual Information(16) |
| 17 | Caplin Point Laboratories Limited | | Mr. D P Mishra | | Non- Executive Non- Independent Director | Any other transaction | Sitting Fees | | NA | 0.006 | 0 | 0 | | | | | | | | | | Textual Information(17) |
| 18 | Caplin Point Laboratories Limited | | Dr. K C John | | Independent Director | Any other transaction | Sitting Fees | | NA | 0.012 | 0 | 0 | | | | | | | | | | Textual Information(18) |
| 19 | Caplin Point Laboratories Limited | | Mr. D Sathyanarayanan | | Independent Director | Any other transaction | Sitting Fees | | NA | 0.008 | 0 | 0 | | | | | | | | | | Textual Information(19) |
| 20 | Caplin Point Laboratories Limited | | Mr. V Thirumalai | | Independent Director | Any other transaction | Sitting Fees | | NA | 0.012 | 0 | 0 | | | | | | | | | | Textual Information(20) |
| 21 | Caplin Point Laboratories Limited | | Mr. R Viswanathan | | Independent Director | Any other transaction | Sitting Fees | | NA | 0.004 | 0 | 0 | | | | | | | | | | Textual Information(21) |
| 22 | Caplin Point Laboratories Limited | | Dr. C K Gariyali | | Independent Director | Any other transaction | Sitting Fees | | NA | 0.004 | 0 | 0 | | | | | | | | | | Textual Information(22) |
| 23 | Caplin Point Laboratories Limited | | Caplin Onco Limited | | Wholly owned Subsidiary | Investment | | 125 | NA | 24.96 | 9.3 | 34.26 | | | | | | | | | | Textual Information(23) |

Total value of ransaction during the reporting

| | Text Block |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Textual Information(1) | |
| Textual Information(2) | |
| Textual Information(3) | |
| Textual Information(4) | |
| Textual Information(5) | |
| Textual Information(6) | As regards transactions between CPL and CSL, the limit mentioned in each line item of Rs. 2.60 C is an aggregate limit for all items mentioned in Sl No. 6 to Sl No. 10 as approved by the Audit Committee and Board of Directors of the respective companies |
| Textual Information(7) | As regards transactions between CPL and CSL, the limit mentioned in each line item of Rs. 2.60 C is an aggregate limit for all items mentioned in Sl No. 6 to Sl No.10 as approved by the Audit Committee and Board of Directors of the respective companies |
| Textual Information(8) | As regards transactions between CPL and CSL, the limit mentioned in each line item of Rs. 2.60 C is an aggregate limit for all items mentioned in St No. 6 to STNo. 10 as approved by the Audit Committee and Board of Directors of the respective companies |
| Textual Information(9) | As regards transactions between CPL and CSL, the limit mentioned in each line item of Rs. 2.60 C is an aggregate limit for all items mentioned in IS No. 6 to SI No. 10 as approved by the Audit Committee and Board of Directors of the respective companies |
| Textual Information(10) | As regards transactions between CPL and CSL, the limit mentioned in each line item of Rs. 2.60 C is an aggregate limit for all items mentioned in Sl No. 6 to Sl No. 10 as approved by the Audit Committee and Board of Directors of the respective companies |
| Textual Information(11) | Loan to be provided in one or more tranches |
| Textual Information(12) | |
| Textual Information(13) | |
| Textual Information(14) | |
| Textual Information(15) | |
| Textual Information(16) | |
| Textual Information(17) | |
| Textual Information(18) | |
| Textual Information(19) | |
| Textual Information(20) | |
| Textual Information(21) | |
| Textual Information(22) | |
| Textual Information(23) | investment to be made in one or more tranches |

